Nanjing Qingpu Biotechnology

Nanjing Qingpu Biotechnology Co., Ltd., operating as Delovabio, is a biopharmaceutical firm established in 2017, concentrating on the development of novel drugs for pain management. The company was co-founded by Dr. Qingsong Wang, who serves as CEO, and Dr. Ning Hu, the Chief Scientific Officer. Dr. Wang holds a Ph.D. from China Pharmaceutical University and brings nearly two decades of experience in new drug R&D, clinical development, and business development, notably from his tenure at Simcere Pharmaceutical Group. Dr. Hu earned his Ph.D. from the University of Southern California and has close to 30 years of experience in complex injectable drug development.

The firm's business model is centered on addressing unmet clinical needs in the global pain market by developing non-addictive, long-acting, and potent non-opioid analgesics. Its revenue generation is anticipated from the commercialization of its product pipeline and through strategic partnerships with established pharmaceutical companies for drug distribution. Qingpu Biotechnology operates with a global focus, maintaining a headquarters and R&D center in Nanjing, China, and a subsidiary in California, USA, to conduct clinical studies and registration in both markets concurrently.

The company has developed a robust pipeline of over ten drug candidates utilizing several proprietary technology platforms. These include the XisGel® sustained-release gel platform for long-acting injections lasting from days to months, the ETPF® topical skin preparation platform, and technologies for enhancing the solubility of poorly soluble drugs. Its leading product, Putanning™ (Meloxicam Injection II), is a long-acting NSAID for post-operative pain management that requires only once-daily administration. This drug has achieved a significant milestone by receiving market approval from both the U.S. FDA and China's NMPA in 2025. Other pipeline products, such as QP002 and QP004 for post-surgical pain, are in the preclinical phase. The company has secured multiple rounds of funding from investors including Legend Capital, Indaco Capital, and a recent B+ round of over 100 million RMB to accelerate commercialization and R&D efforts.

Keywords: pain management, non-opioid analgesics, drug development, biotechnology, pharmaceutical, sustained-release, injectable drugs, postoperative pain, neuropathic pain, controlled-release technology, XisGel, Meloxicam, clinical trials, biopharmaceutical, Nanjing, Dr. Qingsong Wang, long-acting pain relief, drug delivery systems, topical formulations, pharmaceutical innovation